AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28646811
Drug: Tui na
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tui na treatment
Trial: 26110296
Drug: co‐trimoxazole (960
FDA approved: no
EMA approved: no
PMDA approved: no
Description: co‐trimoxazole (960 mg twice a day)
Trial: 26110296
Drug: norfloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: norfloxacin (400 mg twice a day)
Trial: 26110296
Drug: levofloxacin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levofloxacin (250 mg once a day)
Trial: 17114880
Drug: Clopidogrel 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 600 mg loading dose in addition to standard acetylsalicylic acid/heparin treatment
Trial: 15119913
Drug: Supportive clinical
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive clinical environment treatment program
Trial: 29958049
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g oral NAC
Trial: 16914594
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human TSH (rhTSH) preparation
Trial: 16914594
Drug: hypothyroid preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hypothyroid preparation
Trial: 15273269
Drug: Asthma screening
RxNorm normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Asthma screening questionnaire administered to parents
Trial: 11093918
Drug: H(2)-receptor antagonists
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: H(2)-receptor antagonists (cimetidine or ranitidine)
Trial: 11093918
Drug: H(1)-receptor antagonist
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: H(1)-receptor antagonist (mepyramine)
Trial: 11093918
Drug: H(1)- and
RxNorm normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: H(1)- and H(2)-receptor blockade
Trial: 8471592
Drug: Interferon-gamma at
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-gamma at 0.1 mg/m2
Trial: 8471592
Drug: Interferon-gamma at
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-gamma at 0.25 mg/m2
Trial: 8471592
Drug: Interferon-gamma at
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-gamma at 0.01 mg/m2
Trial: 3519353
Drug: Methylergometrin (0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylergometrin (0.125 mg, 3 times a day for 4 weeks)
Trial: 3042354
Drug: urapidil 60
RxNorm normalized name: urapidil 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: urapidil 60 mg twice daily (adjustable to 30 mg, 60 mg, or 90 mg based on blood pressure response)
Trial: 3042354
Drug: captopril 25
RxNorm normalized name: captopril 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: captopril 25 mg twice daily (adjustable to 12.5 mg, 25 mg, or 50 mg based on blood pressure response)
Trial: 25553110
Drug: PEG-IFN therapy
RxNorm normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PEG-IFN therapy
Trial: 16584354
Drug: Antibiotics (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics (250 mg metronidazole and 375 mg amoxicillin three times a day for 7 days)
Trial: 30869644
Drug: App-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: App-based treatment program (Tät app) for SUI, 3-month duration focusing on pelvic floor muscle training (PFMT)
Trial: 30869644
Drug: App-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: App-based treatment program (Tät app) for SUI
Trial: 29574600
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment with near complete or complete recanalization (TICI grades 2b and 3)
Trial: 25486269
Drug: Dopaminergic medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopaminergic medication (various types)
Trial: 9496247
Drug: Subcutaneous glucagon-like
RxNorm normalized name: Glucagon-like peptide II (2-glycine) (human)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous glucagon-like peptide-1(7-36)amide (GLP-1) at a dosage of 0.5 nmol/kg
Trial: 9496247
Drug: Subcutaneous glucagon-like
RxNorm normalized name: Glucagon-like peptide II (2-glycine) (human)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous glucagon-like peptide-1(7-36)amide (GLP-1)
Trial: 2917311
Drug: Tamoxifen in
RxNorm normalized name: Product containing tamoxifen in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen in combination with standard cytotoxic chemotherapy (doxorubicin, cis‐diamminedichloroplatinum)
Trial: 2917311
Drug: Standard cytotoxic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard cytotoxic chemotherapy (doxorubicin, cis‐diamminedichloroplatinum)
Trial: 2917311
Drug: Cytosol steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytosol steroid receptor determinations
Trial: 27053235
Drug: 6.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.5 mg/kg ATG (Thymoglobulin)
Trial: 24713613
Drug: Sulpiride (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulpiride (high dose selective DA D2/3-receptor antagonist)
Trial: 23279492
Drug: Betamethasone (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betamethasone (0.5 mg/kg) administered at 55 days post-ovulation
Trial: 23279492
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution administered at 55 days post-ovulation (Control Group)
Trial: 19852302
Drug: Runmushu Oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Runmushu Oral Liquid (RMS) combined with Hialid eye drops
Trial: 17252006
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron supplementation with subcutaneous epoetin beta 30,000 IU once weekly for 16 weeks
Trial: 17252006
Drug: Subcutaneous epoetin
RxNorm normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous epoetin beta 30,000 IU once weekly for 16 weeks without intravenous iron
Trial: 17252006
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron supplementation with subcutaneous epoetin beta
Trial: 11235144
Drug: LHRH agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LHRH agonist with flutamide (n = 5)
Trial: 11235144
Drug: LHRH agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LHRH agonist mono-therapy (n = 4)
Trial: 9648044
Drug: Stimulant use
RxNorm normalized name: Staphylococcus simulans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulant use as prescribed (Ritalin)
Trial: 9648044
Drug: Stimulant use
RxNorm normalized name: Staphylococcus simulans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulant use (Ritalin)
Trial: 9648044
Drug: Stimulant storage
RxNorm normalized name: Staphylococcus simulans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulant storage policies in schools
Trial: 9648044
Drug: School policies
RxNorm normalized name: schorl tourmaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: School policies regarding prescription drugs
Trial: 9648044
Drug: School policies
RxNorm normalized name: schorl tourmaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: School policies regarding medication carrying
Trial: 31928949
Drug: Subanesthetic ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subanesthetic ketamine (0.5 mg/kg)
Trial: 29450737
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral hygiene intervals (12 and 24 hours)
Trial: 29450737
Drug: Extended oral
RxNorm normalized name: Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended oral hygiene intervals (48 and 72 hours)
Trial: 28194525
Drug: SoluMatrix diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SoluMatrix diclofenac 35 mg TID
Trial: 28194525
Drug: SoluMatrix diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SoluMatrix diclofenac 35 mg BID
Trial: 28194525
Drug: SoluMatrix diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SoluMatrix diclofenac 35 mg TID and BID
Trial: 15522553
Drug: docetaxel‐based chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: docetaxel‐based chemotherapy - six cycles (DXL-epirubicin: 13 patients, DXL alone: 15 patients)
Trial: 11553189
Drug: Metformin 500
RxNorm normalized name: metformin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 500 mg b.i.d. for 6 months
Trial: 8831216
Drug: 100 ml
RxNorm normalized name: PVC IV Bag 100 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml Iopamidol (300 mgI/ml), at a rate of 2 ml/sec
Trial: 8831216
Drug: 120 ml,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 ml, 3 ml/sec
Trial: 8831216
Drug: 150 ml,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 ml, 3 ml/sec
Trial: 8831216
Drug: biphasic method,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: biphasic method, initial 100 ml, 3.3 ml/sec; remaining 50 ml, 1.6 ml/sec
Trial: 2248385
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine and clonidine (group 1; n = 45)
Trial: 2248385
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine alone (group 2; n = 46)
Trial: 7437248
Drug: Colchicine (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine (1.0 mg daily for 8 days)
Trial: 7437248
Drug: Placebo (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (daily for 8 days)
Trial: 30461542
Drug: Rituximab and
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab and Tumor Necrosis Factor Inhibitors (including Certolizumab)
Trial: 26708726
Drug: Intradialytic parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradialytic parenteral nutrition (IDPN) plus standardized nutritional counseling
Trial: 25467396
Drug: Mental practice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mental practice (MP) and mirror therapy (MT) associated with conventional physical therapy training (CPTT)
Trial: 22788263
Drug: Guanfacine extended
RxNorm normalized name: Guanfacine Extended-Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guanfacine extended release (GXR) added to stimulant monotherapy
Trial: 20837589
Drug: Stimulant monotherapy
RxNorm normalized name: Staphylococcus simulans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulant monotherapy
Trial: 1611460
Drug: Dietary calcium
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary calcium supplementation (1.25 g day‐1)
Trial: 31371195
Drug: Ultrasound-guided lumbar
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided lumbar plexus and sciatic nerve blocks with ropivacaine (1.5 mg kg‐1)
Trial: 27765750
Drug: High-dose ebselen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ebselen (150 mg po twice daily)
Trial: 19902197
Drug: Racecadotril 100
RxNorm normalized name: racecadotril 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Racecadotril 100 mg every 8 h
Trial: 19902197
Drug: Loperamide 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loperamide 2.0 mg followed by one tablet after each unformed stool, up to four tablets in any 24-h period
Trial: 17923225
Drug: Self‐etching primer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self‐etching primer (CSE) with 20% polyacrylic acid conditioner (Cavity conditioner, CC) preconditioning after TM application
Trial: 9620116
Drug: PHT sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PHT sodium solution 435 mg intravenously
Trial: 9620116
Drug: PHT acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PHT acid suspension 400 mg
Trial: 9620116
Drug: PHT sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PHT sodium solution 435 mg
Trial: 2191992
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of methylprednisolone (40 mg bolus)
Trial: 2191992
Drug: Divided regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Divided regimen of methylprednisolone (20 mg bolus and 5 mg bolus 8 hours later)
Trial: 475363
Drug: Aminoglycoside treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminoglycoside treatment (gentamicin, tobramycin, or amikacin)
Trial: 31679069
Drug: Treatment-as-usual (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-as-usual (2 weeks of unloading in plaster cast followed by 4 weeks weightbearing in orthosis)
Trial: 28072888
Drug: Early on-treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early on-treatment response at Week 4
Trial: 17623958
Drug: Intravenous PCA
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous PCA tramadol (loading dose of 2.5 mg/kg followed by PCA infusion of 10 mg)
Trial: 17623958
Drug: Intravenous PCA
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous PCA morphine (loading dose of 0.1 mg/kg followed by PCA morphine bolus of 1 mg)
Trial: 17623958
Drug: Intravenous PCA
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous PCA tramadol
Trial: 17623958
Drug: Intravenous PCA
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous PCA morphine
Trial: 11157376
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg of warfarin daily for 12 months
Trial: 11157376
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group (n = 29)
Trial: 9395349
Drug: Zanamivir (GG167)
RxNorm normalized name: Zanamivir
DrugBank: Zanamivir (DB00558)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zanamivir (GG167) intranasally as early treatment
Trial: 8203783
Drug: Daflon 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daflon 500 mg (micronized flavonoidic fraction)
Trial: 3302568
Drug: Naftidrofuryl (Dusodril)
RxNorm normalized name: naftidrofuryl
DrugBank: Naftidrofuryl (DB13588)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naftidrofuryl (Dusodril) in combination with cortison and dextran
Trial: 3302568
Drug: Pentoxifyllin (Trental)
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifyllin (Trental) in combination with cortison and dextran
Trial: 3302568
Drug: Long-term treatment
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term treatment with either naftidrofuryl or pentoxifyllin
Trial: 29495483
Drug: Household water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Household water treatment systems (biosand zeolite-silver impregnated granular clay filters and silver-impregnated porous pot filters) installed in 372 participants from 70 households.
Trial: 24622667
Drug: Stepwise addition
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stepwise addition of bolus insulin (one bolus dose with the largest meal, additional doses at 11 and 22 weeks if HbA1c remained at 7% or higher)
Trial: 24622667
Drug: Full basal-bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full basal-bolus therapy (insulin aspart before every meal)
Trial: 19437243
Drug: Guided active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided active play/physical activity, 60 minutes, twice a week for 5 months
Trial: 15769980
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg dexamethasone twice daily for 5 days
Trial: 10401515
Drug: Naloxone (0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (0, 0.8, 1.6, or 3.2 mg/70 kg)
Trial: 10401515
Drug: Naloxone (lower
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (lower doses)
Trial: 1693037
Drug: Allylestrenol (ALE)
RxNorm normalized name: allylestrenol
DrugBank: Allylestrenol (DB01431)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allylestrenol (ALE) 50 mg/day for 12 weeks
Trial: 1693037
Drug: Chlormadinone acetate
RxNorm normalized name: Chlormadinone acetate
DrugBank: Chlormadinone acetate (DB15903)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlormadinone acetate (CMA) 50 mg/day for 12 weeks
Trial: 331522
Drug: Fluorouracil intraluminal
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluorouracil intraluminal chemotherapy
Trial: 30949704
Drug: Intravenous lefamulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous lefamulin (150 mg, q12h)
Trial: 30949704
Drug: Oral lefamulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral lefamulin (600 mg IR tablet)
Trial: 30949704
Drug: Oral lefamulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral lefamulin (3 × 200 mg capsule)
Trial: 30949704
Drug: Oral lefamulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral lefamulin (IR) in fasted state
Trial: 30949704
Drug: Repeated doses
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated doses of lefamulin (IR, q12h)
Trial: 26209860
Drug: Reboxetine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reboxetine (4 mg/d)
Trial: 26209860
Drug: Amisulpride (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amisulpride (200 mg/d)
Trial: 21611863
Drug: Group Slow
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Slow (1 ml/min injection of hyperbaric 0.5% bupivacaine)
Trial: 21611863
Drug: Group Extra
RxNorm normalized name: Panadol Extra
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Extra Slow (0.5 ml/min injection of hyperbaric 0.5% bupivacaine)
Trial: 19912734
Drug: Sanxue Mingmu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sanxue Mingmu Tablet combined with conventional treatment
Trial: 19912734
Drug: Xueshuantong Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xueshuantong Tablet combined with conventional treatment
Trial: 16698412
Drug: Intranasal lorazepam
RxNorm normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal lorazepam (100 microg/kg)
Trial: 16698412
Drug: Intramuscular paraldehyde
RxNorm normalized name: Paraldehyde
DrugBank: Paraldehyde (DB09117)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular paraldehyde (0.2 mL/kg)
Trial: 15138466
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy as perceived by medical oncologists
Trial: 11336276
Drug: Thin-layer chromatography
RxNorm normalized name: Bayer Aspirin Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thin-layer chromatography (TLC) screening method for drug quality
Trial: 9466167
Drug: RS-8359 100
RxNorm normalized name: (RS)-bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RS-8359 100 mg/day
Trial: 9466167
Drug: RS-8359 200
RxNorm normalized name: (RS)-bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RS-8359 200 mg/day
Trial: 8923574
Drug: Moclobemide 300
RxNorm normalized name: moclobemide 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide 300 mg/day
Trial: 9466167
Drug: RS-8359 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RS-8359 (all doses)
Trial: 23926589
Drug: 11 different
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 11 different toothbrushes (Colgate Massager, Butler 311, Gum Super Tip 463, Oral-B Indicator 35, Colgate Omni, Gum Technique 493)
Trial: 23926589
Drug: Oral-B Indicator
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral-B Indicator 35
Trial: 2895695
Drug: Beta 2-antagonist
RxNorm normalized name: 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN
DrugBank: Hydroxypropyl betadex (DB15379)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta 2-antagonist pretreatment
Trial: 31221941
Drug: Leukocytapheresis (LCAP)
RxNorm normalized name: AUTOLOGOUS CD4+ AND CD8+ T CELLS OBTAINED BY LEUKAPHERESIS, TRANSDUCED WITH AN HIV-DERIVED SELF-INACTIVATING (SIN) LENTIVIRAL VECTOR, ENCODING AN ENHANCED-AFFINITY T CELL RECEPTOR (TCR) SPECIFIC FOR THE HUMAN MELANOMA ANTIGEN A4 (MAGE FAMILY MEMBER A4, A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leukocytapheresis (LCAP) therapy (n = 20)
Trial: 31221941
Drug: Disease-modifying antirheumatic
RxNorm normalized name: ANTIRHEUMATICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disease-modifying antirheumatic drugs (DMARDs) (n = 31)
Trial: 30621787
Drug: Back2School (modular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Back2School (modular transdiagnostic cognitive behavioral therapy)
Trial: 21178123
Drug: Glycerol mixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycerol mixed with cranberry juice (97 ± 3 ml glycerol + equal portion of cranberry juice; n = 9)
Trial: 18778333
Drug: Moxaverine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxaverine (150 mg, administered i.v.)